Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMD3100 plus G-CSF versus G-CSF alone for stem cell mobilization after prior failed collection
2006-004247-29Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in multiple myeloma (MM), non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) comparing G-CSF plus plerixafor with G-CSF plus placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Mar 2009; status: completed.
02
Drugs
plerixafor
03
Conditions
multiple myeloma (MM)non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2006-004247-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004247-29.